Bolt Biotherapeutics, Inc. (BOLT) |
|
1.04 0.03 (2.97%)
|
09-28 16:00 |
|
Open: |
1.11 |
Pre. Close: |
1.01 |
|
High:
|
1.14 |
Low:
|
0.9002 |
|
Volume:
|
2,272,524 |
Market Cap:
|
39(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:49:20 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.37  One year: 1.57 |
| Support: |
Support1: 0.9 Support2: 0.74 |
| Resistance: |
Resistance1: 1.17 Resistance2: 1.35 |
| Pivot: |
1.08 |
| Moving Average: |
MA(5): 1.01 MA(20): 1.08
MA(100): 1.38 MA(250): 1.41 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 14.6 %D(3): 8.5 |
| RSI: |
RSI(14): 43.3 |
| 52-week: |
High: 2.02 Low: 0.9 |
| Average Vol(K): |
3-Month: 106 (K) 10-Days: 298 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BOLT ] has closed above bottom band by 34.5%. Bollinger Bands are 2.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.14 - 1.15 |
1.15 - 1.15 |
|
Low:
|
0.89 - 0.89 |
0.89 - 0.9 |
|
Close:
|
1.03 - 1.04 |
1.04 - 1.05 |
|
Company Description |
|
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. |
Headline News |
Thu, 28 Sep 2023
Health Care Sector Update for 09/28/2023: BXRX, BNOX, BCLI, BOLT - Nasdaq
Thu, 28 Sep 2023
Significant Market Movements on September 28 2023 BNOX PTON ... - Best Stocks
Thu, 28 Sep 2023
Bolt Biotherapeutics annonce que la FDA américaine a désigné le ... - Zonebourse.com
Thu, 28 Sep 2023
Bolt Biotherapeutics Says US FDA Granted Orphan Drug ... - Marketscreener.com
Thu, 28 Sep 2023
Bolt Bio stock spikes on FDA's orphan status (NASDAQ:BOLT) - Seeking Alpha
Thu, 28 Sep 2023
Bolt Biotherapeutics' BDC-1001 Gets FDA Orphan Drug Designation ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
38 (M) |
|
% Held by Insiders
|
1.946e+007 (%) |
|
% Held by Institutions
|
6.5 (%) |
|
Shares Short
|
1,650 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-7.981e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
203.6 |
|
Return on Equity (ttm)
|
-22.7 |
|
Qtrly Rev. Growth
|
6.78e+006 |
|
Gross Profit (p.s.)
|
3.25 |
|
Sales Per Share
|
-49.3 |
|
EBITDA (p.s.)
|
1.82022e+006 |
|
Qtrly Earnings Growth
|
-2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-70 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.03 |
|
Price to Cash Flow
|
0.24 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.5e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
